Model‐informed approach to support pediatric dosing for the pan‐PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors
Abstract Copanlisib is an intravenously administered phosphatidylinositol 3‐kinase (PI3K) inhibitor which was investigated in pediatric patients with relapsed/refractory solid tumors. A model‐informed approach was undertaken to support and confirm an empirically selected starting dose of 28 mg/m2 fo...
Saved in:
Main Authors: | Peter N. Morcos (Author), Jan Schlender (Author), Rolf Burghaus (Author), Jonathan Moss (Author), Adam Lloyd (Author), Barrett H. Childs (Author), Margaret E. Macy (Author), Joel M. Reid (Author), John Chung (Author), Dirk Garmann (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2023-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Copanlisib population pharmacokinetics from phase I-III studies and exposure-response relationships in combination with rituximab
by: Peter N. Morcos, et al.
Published: (2023) -
Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib
by: Krause G, et al.
Published: (2018) -
Validated HPLC method for quantification of copanlisib in mice plasma: application to a pharmacokinetic study
by: Ashok Zakkula, et al.
Published: (2020) -
Results of Vincristine, Cyclophosphamide and Topotecan Protocol in Refractory/Relapsed Pediatric Solid Tumors: A Single-center Experience
by: Uğur Demirsoy, et al.
Published: (2019) -
Novel Therapies for Relapsed and Refractory Neuroblastoma
by: Peter E. Zage
Published: (2018)